Researchers track movements and symptoms during COVID-19 pandemic

New George Mason University College of Health and Human Services study is one of the first individual-level studies to track movements and symptoms during the COVID-19 pandemic.

How can we better understand how people move during the pandemic and how they spread COVID-19? New George Mason University's College of Health and Human Services research is one of the first individual-level studies to explore this question.

Dr. Janusz Wojtusiak led the study published in the Journal of Healthcare Informatics Research. Wojtusiak and colleagues tracked the symptoms and movements of 175 volunteer individuals on George Mason University's campus. They found that there is no evidence that participants altered their movements based on the symptoms they reported.

We could not detect any significant change of movement when people should self-quarantine. On the other hand, some people almost did not leave home since the beginning of the pandemic, while others move freely around."

Dr. Janusz Wojtusiak, George Mason University

Participants used the Mason COVID HealthCheckTM to record symptoms of possible COVID-19 infection and GPS and WiFi data to provide information on how they move during the pandemic. This allows the researchers to model and predict movements during the pandemic and in conjunction with any reported possible COVID-19 symptoms.

"By tracking individual movements and symptoms in our study, our findings could help inform effective public health interventions to reduce COVID-19 infections," explains Wojtusiak.

In addition, Wojtusiak and colleagues analyzed the de-identified Mason COVID HealthCheckTM responses and found that a headache was the most frequently reported symptom, and a headache was always listed as a symptom when any other symptoms were reported. Other commonly reported symptoms were coughs and sore throats.

Movement patterns varied among participants, with some only going out for essential trips while others moved about more. As a group, the movement was consistent over the study period, which included a period when Virginia was under a stay-at-home order and when it was not.

Participants traveled a total average of 139 miles per week, visiting an average of fewer than six locations per week. This low average mileage and number of sites visited does suggest that COVID-19-related restrictions affected their movement.

However, they also found that even when participants reported symptoms of COVID-19 or contact with others with COVID-19, they did not change their movements as recommended by public health guidance.

George Mason University has a very low COVID-19 infection rate, and during the period none of the study participants reported COVID-19 infection, so researchers weren't able to link COVID-19 positive tests and movement.

Future analysis will include data from the winter of 2020 so may provide more information on movement after COVID-19 infection.

The researchers are also conducting surveys and interviews to provide richer data including reasons for complying or not complying with social distancing.

Source:
Journal reference:

Wojtusiak, J., et al. (2021) COVID-19 Symptom Monitoring and Social Distancing in a University Population. Journal of Healthcare Informatics Research. doi.org/10.1007/s41666-020-00089-x.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients